HOME >> MEDICINE >> NEWS
Trials launched to test treatment of cognitive dysfunction in schizophrenia

The National Institute of Mental Health (NIMH), of the National Institutes of Health (NIH), has awarded a four-year, $9 million contract to the University of California, Los Angeles (UCLA) and five other academic medical centers to create a network of Treatment Units for Research on Neurocognition and Schizophrenia (TURNS). The research will test the effectiveness of new drug treatments for the cognitive deficits of schizophrenia. The project will be directed by Stephen R. Marder, M.D., at UCLA with investigators at Harvard's Massachusetts General Hospital, Boston, the University of North Carolina, Chapel Hill, the University of Maryland, Baltimore, Duke University, Durham, Washington University, St. Louis, and Nathan Kline Institute for Psychiatric Research, New York.

Schizophrenia is a chronic, severe, and disabling brain disease. Approximately 1 percent of the population develops schizophrenia during their lifetime -- more than 2 million Americans suffer from the illness in a given year. Although available medications are reasonably effective in treating the positive symptoms of the illness such as hallucinations and delusions, recent research indicates that cognitive impairments in areas such as attention, memory and problem solving are responsible for much of the disability associated with the disease.

"Unfortunately, the medications currently available do little to remedy this aspect of the illness. Consequently, many patients have serious residual symptoms and only one in five are able to recover sufficiently to work," said Thomas R. Insel, M.D., director of NIMH.

The NIMH approach is built on the assumption that progress in developing new treatments will require collaboration between the best academic, government and industry scientists. The TURNS is one component of a multipronged NIMH effort to stimulate academic and industry sponsored research focused on cognitive deficits in schizophrenia. It follows completion of the Measuremen
'"/>

Contact: Jennifer Loukissas
nimhpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health
5-May-2004


Page: 1 2

Related medicine news :

1. Randomisation phase of the DIRECT programme (DIabetic REtinopathy Candesartan Trials) completed
2. Trials on hormone therapy and hypertension treatment change practice, medication usage of patients
3. Clinical Trials Litigation: Legal & Ethical Issues in Human Subjects Research
4. New awards, expanded focus for Pediatric AIDS Clinical Trials Group
5. AAPS Workshop to Examine Chemistry and Manufacturing Controls Trials, Emerging Products
6. Mayo Clinic Study Finds Costs For Cancer Clinical Trials Comparable To Costs For Standard Treatment
7. Retrospective Statistical Analysis Corroborates Early Results Of Randomized Breast Cancer Trials
8. Scientific Trials Of So-Called Wonder Hormone Treatment For Autism Will Be Conducted In Seattle, Denver
9. Clinical Trials Announced Using Non-Invasive Innovative MRI To Diagnose Breast Tumors
10. History In The Making: The Discovery And Clinical Trials Of Viagra
11. OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/11/2019)... ... 2019 , ... Global Education Group (Global), a division of ... the official accreditor for PAINWeek, the largest US pain conference for frontline practitioners. ... has done for the past ten years. In addition, the Global team introduced ...
(Date:9/11/2019)... ... September 11, 2019 , ... GRM Information Management, ... Health Data and Information Conference in Chicago, Illinois September 14 to 18. ... more about GRM’s healthcare information management solutions . , Built around their ...
(Date:9/11/2019)... ... September 11, 2019 , ... Autopsies don’t lie. They report the causes ... , Methamphetamine permanently harms the heart. It increases risks of heart attack and ... of how the damage occurs. , An August 1, 2019 article in ...
(Date:9/11/2019)... ... September 11, 2019 , ... Ahipoki is excited to ... poke bowl option appeals to vegans, vegetarians, pescatarians and poke bowl fans alike. ... sesame oil. With its meaty texture similar to tuna, Ahipoki customers ...
(Date:9/11/2019)... ... September 10, 2019 , ... Women’s Excellence is excited to announce ... at 32686 Woodward Ave, Suite 103, Royal Oak, MI 48073 in the heart of ... offers comprehensive women’s health services in a contemporary, spa-like atmosphere. We are thrilled ...
Breaking Medicine News(10 mins):
(Date:9/17/2019)... ... September 17, 2019 , ... Today, in partnership with ... contraception and consent with student and faculty from The City University of New ... Francisco Ramirez, MPH; Elise Schuster, MPH; Raffaele M. Bernardo, DO, FACP, AAHIVS and ...
(Date:9/17/2019)... ... September 17, 2019 , ... Embr Labs , the ... Series B funding led by DigiTx Partners, with participation from Safar Partners, ... use the investment to grow the company’s footprint in wellness and digital therapeutics, accelerate ...
(Date:9/17/2019)... ... September 17, 2019 , ... Gustavo Grodnitzky, PhD will join the ... Yoga Science as holistic mind/body medicine for physicians and other health care professionals. Entitled ... 22-26, 2019 at the Cranwell Resort and Spa in Lenox, Massachusetts, is accredited by ...
Breaking Medicine Technology:
Cached News: